SCHEMBL7041674

SCHEMBL7041674

CCN(CC)c1ccc(-c2csc(CN)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.45
TAAR1 Q96RJ0 1/20 0.44
ALDH1A1 P00352 7/20 0.43
RAB9A P51151 4/20 0.43
L3MBTL1 Q9Y468 4/20 0.43
MEN1 O00255 6/20 0.43
KMT2A Q03164 5/20 0.43
GAA P10253 2/20 0.43
NPC1 O15118 2/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
ATP4A P20648 2/20 0.43
ATP4B P51164 2/20 0.43
EPHA2 P29317 1/20 0.41
KDR P35968 1/20 0.41
EPHB4 P54760 1/20 0.41
MAPK1 P28482 2/20 0.41
TDP1 Q9NUW8 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL172198 0.83 LTA4H (0.54) ALDH1A1RAB9AL3MBTL1MEN1KMT2A
Bromide SCHEMBL6832827 0.81 RAB9A (0.56) ALDH1A1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL7035076 0.80 ALDH1A1 (0.58) ALDH1A1RAB9AMEN1KMT2AGAA
SCHEMBL16217968 0.79 RAB9A (0.65) LOXL2TAAR1ALDH1A1RAB9AL3MBTL1
Bromide SCHEMBL6830057 0.78 ALDH1A1 (0.57) ALDH1A1RAB9AMEN1KMT2AGAA
SCHEMBL7038615 0.77 MEN1 (0.46) LOXL2TAAR1ALDH1A1RAB9AMEN1
SCHEMBL19625329 0.76 NPC1 (0.43) ALDH1A1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL7041676 0.76 NPC1 (0.60) ALDH1A1RAB9AMEN1KMT2AGAA
SCHEMBL13341093 0.76 NPC1 (0.43) ALDH1A1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL21812776 0.76 RAB9A (0.66) LOXL2TAAR1ALDH1A1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030158199-A1 Novel compounds for inhibition of Tie-2 KYLIX, B.V. (NL) 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158199-A1 Novel compounds for inhibition of Tie-2 TIE1, TEK, KDR LOXL2 220/4885TAAR1 2505/4885ALDH1A1 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.